| HOME >> BIOLOGY >> TECHNOLOGY |
Tussle Between Tasigna and Sprycel, to Break Into the Gleevec Empire II-15
Table 9: A Review of the Effectiveness of Sprycel and Tasigna in the Treatment of Chronic Myeloid Leukaemia (CML): Percentage Breakdown of Efficiency Levels by Clinical Endpoints As a Measure of Patient Response (includes corresponding Graph/Chart) II-16
Challenges Ahead for Tykerb II-16
Nexavar Shows Promise in the HCC Market II-17
Key Statistical Findings II-18
Table 10: Global Tykerb Market (2007&2015): Percentage Breakdown of Revenue by Indication - Breast Cancer (HER2 positive) 1st, Breast Cancer (HER2 positive) 2nd, Breast Cancer (HER2 positive) 3rd, Breast Cancer (HER2 positive) Brain, H&N adjuvant, Gastric (HER2 positive) 2nd line and Adjuvant Breast (HER2 positive) (includes corresponding Graph/Chart) II-18
Table 11: Tykerb Market (2009 & 2015): Percentage Breakdown of Dollar Sales by Region - US, Europe and Rest of World (includes corresponding Graph/Chart) II-18
Table 12: Global Sales of Iressa in the Treatment of NSCLC (2009E): Percentage Breakdown by First Line NSCLC, Second Line NSCLC and Third Line NSCLC (includes corresponding
Graph/Chart) II-19
Table 13: Global Sales of Nexavar (2009 & 2015P): Percentage Breakdown of Dollar Sales by Indication - Renal Cell Carcinoma, Hepato Cellular Carcinoma, Melanoma, and Non-small Cell Lung Cancer (includes corresponding Graph/Chart) II-19
Table 14: Global Sales of Nexavar (2009 & 2015P): Percentage Breakdown of Dollar Sales by Geographic Region/Country - United States, Europe, and Rest of World (includes corresponding Graph/Chart) II-20
Table 15: Global Tarceva Market (2009 & 2015): Percentage Breakdown of Patient Penetration (%) in Treatment of First Line NSCLC, First line Maintenance Therapy following Avastin in NSCLC, Second line NSCLC, and Thi
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |